E-Book, Englisch, 286 Seiten, eBook
Pujade-Lauraine / Ray-Coquard / Lécuru Ovarian Cancers
1. Auflage 2017
ISBN: 978-3-319-32110-3
Verlag: Springer International Publishing
Format: PDF
Kopierschutz: 1 - PDF Watermark
Advances through International Research Cooperation (GINECO, ENGOT, GCIG)
E-Book, Englisch, 286 Seiten, eBook
ISBN: 978-3-319-32110-3
Verlag: Springer International Publishing
Format: PDF
Kopierschutz: 1 - PDF Watermark
Zielgruppe
Professional/practitioner
Autoren/Hrsg.
Weitere Infos & Material
Ovarian cancer management.- Clinical research in Europe dedicated to ovarian cancers.- Oncogenetics.- Debulking surgery: Interval debulking surgery vs primary: pro and con. How to evaluate quality.- How to evaluate tumor burden before therapeutic decision.- Value of lymphadenectomy.- HYPEC: what is the evidence?.- Onco-fertility applied to ovarian cancers.- First-line systemic therapy (chemo/antiangiogenics).- Elderly.- Treatment at relapse (surgery & systemic treatments).- How to evaluate QoL.- The future in ovarian cancers & place of the new immunotherapies in ovarian cancers.- Particular types of ovarian cancers.- High grade serous carcinoma & BRCA mutation anti-PARP.- Borderline and low grade carcinoma.- Clear Cell carcinoma.- Endometrioid carcinoma.- Mucinous carcinoma.- Carcinosarcoma.- Germ cell tumors.- Sex cord tumors.- Very rare ovarian malignant tumors including small cell carcinoma.
Ovarian cancer management.- Clinical research in Europededicated to ovarian cancers.-
Oncogenetics.- Debulking surgery: Interval debulking surgery vs primary: pro and con. How to evaluate quality.- How to evaluate tumor burden before therapeutic decision.- Value of lymphadenectomy.- HYPEC: what is the evidence?.- Onco-fertility applied to ovarian cancers.- First-line systemic therapy (chemo/antiangiogenics).- Elderly.- Treatment at relapse (surgery & systemic treatments).- How to evaluate QoL.- The future in ovarian cancers & place of the new immunotherapies in ovarian cancers.- Particular types of ovarian cancers.- High grade serous carcinoma & BRCA mutation anti-PARP.- Borderline and low grade carcinoma.- Clear Cell carcinoma.- Endometrioid carcinoma.- Mucinous carcinoma.- Carcinosarcoma.- Germ cell tumors.- Sex cord tumors.- Very rare ovarian malignant tumors including small cell carcinoma.